FDA Suspends Chikungunya Vaccine Over Safety Concerns
The U.S. Food and Drug Administration (FDA) announced on Aug. 22, 2025 that it has suspended the license for French drugmaker Valneva’s chikungunya vaccine, warning that its continued use “poses a danger to public health” following a risk–benefit analysis conducted by the agency’s Center for Biologics Evaluation and Research (CBER). The decision came after reports […]